Logo image of BBLG

BONE BIOLOGICS CORP (BBLG) Stock Fundamental Analysis

NASDAQ:BBLG - US0980705018 - Common Stock

2.2 USD
+0.03 (+1.38%)
Last: 8/22/2025, 8:00:02 PM
2.2 USD
0 (0%)
After Hours: 8/22/2025, 8:00:02 PM
Fundamental Rating

2

Taking everything into account, BBLG scores 2 out of 10 in our fundamental rating. BBLG was compared to 549 industry peers in the Biotechnology industry. BBLG has a great financial health rating, but its profitability evaluates not so good. BBLG has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

BBLG had negative earnings in the past year.
In the past year BBLG has reported a negative cash flow from operations.
BBLG had negative earnings in each of the past 5 years.
BBLG had a negative operating cash flow in each of the past 5 years.
BBLG Yearly Net Income VS EBIT VS OCF VS FCFBBLG Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M -20M -25M

1.2 Ratios

Looking at the Return On Assets, with a value of -236.43%, BBLG is doing worse than 90.89% of the companies in the same industry.
BBLG has a Return On Equity of -256.83%. This is in the lower half of the industry: BBLG underperforms 70.31% of its industry peers.
Industry RankSector Rank
ROA -236.43%
ROE -256.83%
ROIC N/A
ROA(3y)-148.84%
ROA(5y)N/A
ROE(3y)-181.01%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BBLG Yearly ROA, ROE, ROICBBLG Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 2K -2K -4K -6K -8K -10K

1.3 Margins

BBLG does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BBLG Yearly Profit, Operating, Gross MarginsBBLG Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

7

2. Health

2.1 Basic Checks

Compared to 1 year ago, BBLG has more shares outstanding
Compared to 5 years ago, BBLG has more shares outstanding
BBLG has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
BBLG Yearly Shares OutstandingBBLG Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100K 200K 300K 400K
BBLG Yearly Total Debt VS Total AssetsBBLG Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M

2.2 Solvency

BBLG has an Altman-Z score of -32.20. This is a bad value and indicates that BBLG is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -32.20, BBLG is doing worse than 88.16% of the companies in the same industry.
There is no outstanding debt for BBLG. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -32.2
ROIC/WACCN/A
WACCN/A
BBLG Yearly LT Debt VS Equity VS FCFBBLG Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5M -5M 10M -10M

2.3 Liquidity

A Current Ratio of 12.59 indicates that BBLG has no problem at all paying its short term obligations.
With an excellent Current ratio value of 12.59, BBLG belongs to the best of the industry, outperforming 85.61% of the companies in the same industry.
BBLG has a Quick Ratio of 12.59. This indicates that BBLG is financially healthy and has no problem in meeting its short term obligations.
BBLG has a better Quick ratio (12.59) than 85.61% of its industry peers.
Industry RankSector Rank
Current Ratio 12.59
Quick Ratio 12.59
BBLG Yearly Current Assets VS Current LiabilitesBBLG Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 62.21% over the past year.
EPS 1Y (TTM)62.21%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%66.92%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 36.50% on average over the next years. This is a very strong growth
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y86.23%
EPS Next 2Y36.5%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
BBLG Yearly EPS VS EstimatesBBLG Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 -200 -400 -600 -800

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

BBLG reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for BBLG. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BBLG Price Earnings VS Forward Price EarningsBBLG Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BBLG Per share dataBBLG EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -5 -10 -15 -20

4.3 Compensation for Growth

BBLG's earnings are expected to grow with 36.50% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y36.5%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for BBLG!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BONE BIOLOGICS CORP

NASDAQ:BBLG (8/22/2025, 8:00:02 PM)

After market: 2.2 0 (0%)

2.2

+0.03 (+1.38%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-14 2025-08-14/amc
Earnings (Next)11-12 2025-11-12/amc
Inst Owners0.37%
Inst Owner Change-98.25%
Ins Owners0.04%
Ins Owner Change0%
Market Cap3.96M
Analysts82.86
Price Target22.95 (943.18%)
Short Float %2%
Short Ratio0.05
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)21.02%
Min EPS beat(2)7.39%
Max EPS beat(2)34.64%
EPS beat(4)3
Avg EPS beat(4)-48.12%
Min EPS beat(4)-287.25%
Max EPS beat(4)52.74%
EPS beat(8)7
Avg EPS beat(8)12.04%
EPS beat(12)10
Avg EPS beat(12)-1.96%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)36.36%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-81.25%
EPS NY rev (1m)0%
EPS NY rev (3m)-58.2%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.36
P/tB 1.36
EV/EBITDA N/A
EPS(TTM)-21.15
EYN/A
EPS(NY)-4.07
Fwd EYN/A
FCF(TTM)-2.08
FCFYN/A
OCF(TTM)-2.08
OCFYN/A
SpS0
BVpS1.62
TBVpS1.62
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -236.43%
ROE -256.83%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-148.84%
ROA(5y)N/A
ROE(3y)-181.01%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 12.59
Quick Ratio 12.59
Altman-Z -32.2
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)62.21%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%66.92%
EPS Next Y86.23%
EPS Next 2Y36.5%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y55.25%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y7.69%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y7.69%
OCF growth 3YN/A
OCF growth 5YN/A